Rinovum Women’s Health develops and markets The Stork products, including The Stork OTC, a home-use cervical cap insemination aid designed to help couples conceive privately. The company received FDA clearance for over-the-counter use of its product in July 2014. Since that clearance it has launched in three markets: the United States, Canada and the United Kingdom, with product available at select retailers and online. The Stork OTC incorporates a condom-like collection sheath and a tampon-like delivery/removal cap to enable at-home use before or after more costly in-clinic treatments. Rinovum emphasizes affordability and ease-of-use as core product attributes and says customer feedback, including reports of pregnancies, is driving its intent to continue worldwide expansion. The company is privately held and has been supported by regional investors and incubators. Intimate Bridge 2 Conception (Ib2C) is a Pittsburgh-based direct-to-consumer medical device company focused on reproductive health. Led by founder and CEO Steve Bollinger, the company develops healthcare products to help women and couples achieve reproductive goals. Its lead product, the Stork, is a proprietary, non-pharmaceutical device intended to assist couples with conception at home and is being evaluated by the FDA for safety and effectiveness. Ib2C positions the Stork as an alternative to assisted reproductive technology (ART). The company closed a $4.3M Series A financing and said it will use the capital for manufacturing and marketing to prepare for the product's planned 2012 launch. The financing was reported on December 22, 2011. Intimate Bridge to Conception, Inc. is a newly formed Pittsburgh, PA-based medical device company focused on reproductive health to aid natural fertility and conception at home. Launched in September by founder and CEO Stephen Bollinger, the company provides healthcare products designed to help women and couples reach their reproductive goals. Its lead technology, Focus Touch™, is a take-home, conception aid system designed to have similar results to Interauterine insemination (IUI). The company received $475k in equity funding to support its development efforts. The proceeds from the investment will be used to help bring its product to market. Intimate Bridge to Conception aims to offer a private, at-home alternative to clinical fertility procedures.

Total raised

$8M

Funding rounds

3

Latest round

Series C

Latest activity

Dec 2014